



Advances in Multiple Myeloma Research and Treatment

Collection Editor:

Prof. Dr. Katja Weisel

Universitätsklinikum Hamburg-
Eppendorf, Hamburg, Germany

Message from the Collection Editor

Dear Colleagues,

Multiple myeloma represents the second common hematologic malignancy. During the past decades, unprecedented progress was made in research with a focus on understanding myeloma biology and the development of novel drugs directly targeting the malignant cell and its surrounding microenvironment, which translated directly in a markedly improved prognosis of patients affected with this disease. Most recently, emerging cellular treatment options and novel antibody constructs are entering the treatment armamentarium. However, despite all the progress made, multiple myeloma so far remains an incurable and in the majority of patients life limiting disease with still subgroups of patients with a still impaired prognosis, e.g., with high-risk myeloma or being refractory to the established treatment options of special unmet need for novel developments. This Special Issue reflects the recent advances in research and treatment, working toward turning myeloma into a curable disease.

Prof. Katja Weisel
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)